Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 14/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | BTK | Q06187 | 2/20 | 0.47 |
| ▸ | JAK3 | P52333 | 6/20 | 0.45 |
| ▸ | JAK1 | P23458 | 6/20 | 0.44 |
| ▸ | JAK2 | O60674 | 4/20 | 0.44 |
| ▸ | FLT3 | P36888 | 2/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | BRD2 | P25440 | 2/20 | 0.44 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.44 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.44 |
| ▸ | BUB1B | O60566 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | WEE1 | P30291 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4974556 | 0.93 | BRD4 (0.50) | BRD4EGFRBTKJAK3JAK1 | |
| SCHEMBL4973750 | 0.92 | BRD4 (0.51) | BRD4EGFRBTKJAK3JAK1 | |
| SCHEMBL4974697 | 0.92 | BRD4 (0.53) | BRD4JAK3JAK1JAK2FLT3 | |
| SCHEMBL4971316 | 0.91 | BRD4 (0.49) | BRD4EGFRBTKJAK3JAK1 | |
| SCHEMBL4971380 | 0.91 | BRD4 (0.53) | BRD4EGFRBTKJAK3JAK1 | |
| SCHEMBL4973231 | 0.91 | BRD4 (0.53) | BRD4EGFRBTKJAK3JAK1 | |
| SCHEMBL4973481 | 0.90 | BRD4 (0.52) | BRD4EGFRBTKJAK3JAK1 | |
| SCHEMBL4972152 | 0.90 | BRD4 (0.52) | BRD4EGFRBTKJAK3JAK1 | |
| SCHEMBL4973593 | 0.90 | BRD4 (0.48) | BRD4EGFRBTKJAK3JAK1 | |
| SCHEMBL4976750 | 0.88 | BRD4 (0.46) | BRD4EGFRBTKJAK3JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962643-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | claimed |
| EP-1991532-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Rigel Pharmaceuticals, Inc. (US) | 2008-11-19 | — | — | EP | claimed |
| WO-2007098507-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | WO | claimed |
| US-20070203162-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | claimed |
| EP-1991532-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2017-01-11 | — | — | EP | disclosed |
| US-9481654-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20150158824-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-8962643-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| EP-1991532-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Rigel Pharmaceuticals, Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007098507-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| US-20070203162-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203162-A1 | Prevent transplant rejection; autoimmune diseases | JAK3, JAK1, JAK2 | BRD4 2296/4885EGFR 1716/4885BTK 50/4885 |
| US-20150158824-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | BRD4 538/4885EGFR 529/4885BTK 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.